Xilio Therapeutics (XLO) Operating Expenses (2020 - 2026)
Xilio Therapeutics (XLO) posted Operating Expenses of $26.8 million for Q1 2026, up 4.85% sequentially from $25.5 million in Q4 2025, and up 59.47% YoY from $16.8 million in Q1 2025.
Xilio Therapeutics (XLO) Operating Expenses (2020 - 2026) Analysis & Trends
Xilio Therapeutics has reported Operating Expenses for 7 years, with the latest figure at $26.8 million in Q1 2026.
- Quarterly Operating Expenses rose 59.47% year-over-year to $26.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $95.7 million (up 44.56% YoY) and the FY2025 annual result came in at $85.7 million, up 28.12% from the prior year.
- Operating Expenses climbed to $26.8 million in Q1 2026 per XLO's latest filing, from $25.5 million in the prior quarter.
- Over five years, Operating Expenses peaked at $26.8 million in Q1 2026 and troughed at $15.4 million in Q4 2024.
- A 5-year average of $20.5 million and a median of $20.2 million in 2022 frame the typical range for Operating Expenses.
- The sharpest annual moves came in 2024 and 2025: Operating Expenses dropped 25.67% in 2024, then surged 66.23% in 2025.
- Over 5 years, Operating Expenses stood at $23.2 million in 2022, then dropped by 21.74% to $18.1 million in 2023, then slipped by 15.32% to $15.4 million in 2024, then soared by 66.23% to $25.5 million in 2025, then rose by 4.85% to $26.8 million in 2026.
- According to Business Quant data, Operating Expenses over the past three periods registered $26.8 million, $25.5 million, and $21.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 2.89 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 960.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.21 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.06 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 427.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 541.02 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -784.57 Mn |
| 10 | Xilio Therapeutics | 177.75 Mn | 41.71 Mn | - | 22.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.18 Mn |
| Mar 31, 2026 | 26.76 Mn |
| Dec 31, 2025 | 25.52 Mn |
| Sep 30, 2025 | 21.00 Mn |
| Jun 30, 2025 | 22.45 Mn |
| Mar 31, 2025 | 16.78 Mn |
| Dec 31, 2024 | 15.35 Mn |
| Sep 30, 2024 | 17.03 Mn |
| Jun 30, 2024 | 17.06 Mn |
| Mar 31, 2024 | 17.49 Mn |
| Dec 31, 2023 | 18.13 Mn |
| Sep 30, 2023 | 17.36 Mn |
| Jun 30, 2023 | 20.12 Mn |
| Mar 31, 2023 | 23.53 Mn |
| Dec 31, 2022 | 23.17 Mn |
| Sep 30, 2022 | 20.21 Mn |
| Jun 30, 2022 | 24.55 Mn |
| Mar 31, 2022 | 21.22 Mn |
| Dec 31, 2021 | 19.56 Mn |
| Sep 30, 2021 | 15.96 Mn |